-
Policy Matters
Patient Advocacy Is Driving ChangePatient advocates strengthen every aspect of research, from funding innovative science and informing research design, to leading efforts on Capitol Hill to build support for research.
by Carrie Treadwell, MBA
-
Understanding Stress and Cancer
A symposium at the AACR Annual Meeting explores how social factors contribute to elevated risk of cancer in some populations.
by Eric Fitzsimmons
-
The Impact of the RACE for Children Act
Legislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but trials in people under 18 may take years to generate results.
by Marci A. Landsmann
-
Making Collaboration More Common for Rare Cancers
An AACR Annual Meeting 2022 session highlights the impact of research advocacy partnerships for a variety of cancers.
by Marci A. Landsmann
-
Medicaid: A Partial Safety Net
Expansions in coverage and eligibility through the Affordable Care Act have made Medicaid a lifeline for many people with cancer, but benefits vary from state to state.
by Sharon Tregaskis
-
Forward Look
Adequate RepresentationMedical oncologist Lola Fashoyin-Aje describes the Food and Drug Administration’s efforts to make clinical trials more inclusive.
by Erin O'Donnell
-
Get Involved
Doing Yoga in RecoveryA volunteer program brings yoga to cancer patients in the hospital.
by Bradley Jones
-
Facts and Stats
Fifty Years of Growing SurvivorshipMore people in the U.S. are alive after being diagnosed with cancer than ever before.
by Eric Fitzsimmons
-
Policy Matters
Cancer Research: The Key to Tomorrow’s CuresThe AACR is engaging with Congress and the Biden administration on the importance of funding for cancer research.
by David A. Tuveson, MD, PhD
-
Oncology Takes on Cannabis
People take cannabis to treat an array of cancer-related symptoms and side effects. Legal prohibitions have stymied attempts at research into cannabis in cancer patients, but doctors are finding creative ways to study its effects.
by Kate Yandell
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore